Sanofi CEO Paul Hudson says his firm’s twin-track pursuit of a vaccine for COVID-19 means it will have an increased chance of success and a head start in preparing for possible future pandemics.
The company is using both its established recombinant protein-based (baculovirus) technology and a newly licensed mRNA platform to develop two...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)